Multiple Myeloma, Version 3.2022: Featured Updates to the NCCN Guidelines

Natalie S. Callander, Muhamed Baljevic, Kehinde Adekola, Larry D. Anderson, Erica Campagnaro, Jorge J. Castillo, Caitlin Costello, Srinivas Devarakonda, Noura Elsedawy, Matthew Faiman, Alfred Garfall, Kelly Godby, Jens Hillengass, Leona Holmberg, Myo Htut, Carol Ann Huff, Malin Hultcrantz, Yubin Kang, Sarah Larson, Michaela LiedtkeThomas Martin, James Omel, Douglas Sborov, Kenneth Shain, Keith Stockerl-Goldstein, Donna Weber, Ryan A. Berardi, Rashmi Kumar, Shaji K. Kumar

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with various plasma cell neoplasms, including multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates/changes specific to the treatment of patients with multiple myeloma in the 2022 version of the guidelines.

Original languageEnglish
Pages (from-to)8-19
Number of pages12
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume20
Issue number1
DOIs
StatePublished - Jan 2022

Fingerprint

Dive into the research topics of 'Multiple Myeloma, Version 3.2022: Featured Updates to the NCCN Guidelines'. Together they form a unique fingerprint.

Cite this